Phase 3 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) that has been confirmed by lab testing, has not been treated before, can be surgically removed, and is classified as Stage II, IIIA, or IIIB (N2) using standard cancer staging guidelines.
• People whose cancer did not completely disappear (no full pathological response) after receiving pre-surgery chemotherapy combined with a drug called pembrolizumab, followed by surgery.
• People whose cancer test results show that a particular targeted therapy (directed at a gene change called EGFR) is not the recommended treatment — meaning their tumour does not have certain specific EGFR gene changes.
• People who are generally well and able to carry out daily activities, as measured by a standard health performance scale scored at 0 or 1, assessed within 7 days before the first study treatment.
• People living with HIV, provided their HIV is well controlled with anti-retroviral medication.
• People who have hepatitis B, provided they have been on hepatitis B antiviral treatment for at least 4 weeks and have no detectable hepatitis B virus in their blood at the time of joining the trial.
• People with a history of hepatitis C, provided no hepatitis C virus is detectable in their blood at the screening stage.

Who may not be able to join:

• People diagnosed with small cell lung cancer, or whose tumour contains small cell elements, a large-cell neuroendocrine tumour, a sarcomatoid carcinoma, or a Pancoast tumour (a tumour located at the top of the lung).
• People whose local test results show a specific gene rearrangement in a gene called ALK.
• People who have already received any pre-surgery treatment for their current lung cancer diagnosis.
• People who have previously been treated with certain immune-based therapies that target specific proteins involved in the immune system's response to cancer (such as PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137 directed agents).
• People who have previously received any other systemic (whole-body) cancer treatment or experimental treatments beyond what is specifically outlined in this trial's protocol.
• People who have previously received a cancer vaccine.
• People who have received radiation therapy within 2 weeks before the start of the study treatment, or who still have side effects from radiation that require steroid medication.
• People who have received a live or live-attenuated vaccine (a vaccine made with a weakened live virus) within 30 days before the first dose of study treatment.

Important: Always verify eligibility with the trial site directly before applying.